RecruitingNCT06556914

Effect of Albumin Replacement on Oxygen Delivery in Sepsis Patients


Sponsor

Samsun University

Enrollment

45 participants

Start Date

Nov 15, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

Fluid resuscitation is a critical component of sepsis treatment. Research has shown that intravenous (IV) fluid therapy in sepsis positively impacts cardiac output and thereby oxygen (O2) delivery through a complex interaction of central venous pressure, right atrial pressure, venous resistance, ventricular compliance, cardiac contractility, and systemic vascular resistance. The 2021 sepsis prevention guidelines recommend balanced crystalloids as first-line therapy. However, no studies in the literature have evaluated the effect of albumin on O2 delivery. In our study, the investigators aim to assess the impact of albumin replacement on O2 delivery in sepsis patients in the intensive care unit.


Eligibility

Min Age: 18 Years

Inclusion Criteria3

  • Followed up with a diagnosis of sepsis,
  • over 18 years old
  • Patients who were diagnosed with hypo-albuminemia after more than 4L/day fluid resuscitation and underwent albumin replacement

Exclusion Criteria6

  • Consent is not given by the patient or his/her guardian,
  • The initial cause of shock was hypovolemic, cardiogenic or obstructive shock.
  • Pregnancy or suspected pregnancy
  • Peripheral limb or severe organ ischemia with peripheral artery disease
  • Cardiac functions cannot be evaluated optimally by transthoracic echocardiography
  • Patients who died within the first 24 hours after intensive care admission

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Samsun University

Samsun, Ilkadım, Turkey (Türkiye)

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06556914


Related Trials